The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression.

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t working, but it’s not without risk.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, health care providers have had few options to offer patients much-needed symptom improvement,

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Spravato, which is derived from ketamine, is not a new drug—it first ... Despite the approval, Johnson & Johnson’s stock (JNJ) dipped Wednesday after the company’s quarterly earnings release.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal ... Spravato, which is derived from ketamine, is not a new drug—it first came on the market in 2019.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.